GenNBio will become an enterprise which endeavors to be a leader of the bio industry leading the 21st century.
GenNBio has entered into the bio business with the ambitious goal and mission of human health and extension of life.
We are bringing to perfection our biological platform that is required to develop a variety of new medicines using xenotransplantation and immune system technologies, through the acquisition of APR Lab Co., Ltd., a non-clinical CRO specializing in primate studies, our comprehensive partnership with Medi Kinetics Co., Ltd., specializing in laboratory swine development, and our research partnerships with other clinicians in various areas.
We will grow into an enterprise leading the market, respect the value of life, and worthy of winning confidence.
We thank you for your support and ask for continuing encouragement for GenNBio.
Chief Executive Officer of GenNBio
Kim Sung-Joo, Lee Hong-Min